Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
4(100.0%)
4Total
N/A(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06910111Not ApplicableNot Yet Recruiting

CAPTURE Study (Polyglucosamine for Cardio & Atherosclerosis Prevention and Treatment Via Fat Uptake REduction)

Role: collaborator

NCT05244148Not ApplicableTerminated

Two Seawater-based Formulations for Relief of Nasal Congestion in Paediatric Subjects

Role: collaborator

NCT03823560Not ApplicableUnknown

Performance and Safety of Class IIb MD Celegyn® in VVA

Role: collaborator

NCT03833076Not ApplicableCompleted

A New Class IIb MD in Proctological Disorders

Role: collaborator

All 4 trials loaded